UUniversal Diagnostics — Series B · approximately $70M
Sevilla-founded liquid-biopsy company Universal DX announced the initial closing of a Series B of approximately $70M (about €64M) alongside a strategic collaboration with Quest Diagnostics to bring its Signal-C colorectal cancer blood test to the US. Investors include Quest Diagnostics and CDTI's Innvierte programme co-investing with an Adepa RAIF; the company also lists Cambridge, MA, Madrid and Ljubljana offices.
Lead not disclosed
RoundSeries B
Announced20 Nov 2023 · as Universal DX
CityMadrid · reported Sevilla
SectorHealthtech & Bio · Biotech / cancer diagnostics
Source
P
P
The company
Investors 3
CCDTI Innvierte
www.cdti.es
Profile: Centro para el Desarrollo Tecnológico y la Innovación
Q
Quest Diagnostics
UUniversal DX S.C.A. SICAV-RAIF (Adepa)